Jazz Pharma Plc (JAZZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -356,148 | -559,599 | -811,011 | -92,541 | 560,120 |
| Depreciation Amortization | 696,297 | 517,128 | 338,882 | 164,873 | 660,067 |
| Income taxes - deferred | -444,971 | -381,662 | -110,252 | -43,833 | -208,327 |
| Accounts receivable | -106,279 | -40,466 | 10,530 | 66,049 | -21,115 |
| Accounts payable and accrued liabilities | 39,851 | 68,823 | 6,465 | 19,131 | -20,073 |
| Other Working Capital | 18,899 | 91,638 | -39,212 | 287,904 | -76,720 |
| Other Operating Activity | 1,508,124 | 1,297,393 | 1,123,237 | 28,201 | 501,956 |
| Operating Cash Flow | $1,355,773 | $993,255 | $518,639 | $429,784 | $1,395,908 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -470,275 | -140,175 | 99,950 | -130,050 | -460,125 |
| PPE Investments | -888,638 | -900,076 | -26,848 | -13,881 | -38,070 |
| Net Acquisitions | N/A | N/A | -858,053 | N/A | N/A |
| Purchase Sale Intangibles | -151,000 | -97,500 | -25,000 | -25,000 | -10,000 |
| Other Investing Activity | -151,000 | -97,500 | -25,000 | -25,000 | -10,000 |
| Investing Cash Flow | $-1,509,913 | $-1,137,751 | $-809,951 | $-168,931 | $-508,195 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 980,767 |
| Debt Repayment | -781,000 | -773,250 | -765,500 | -757,750 | -606,000 |
| Common Stock Issued | 107,863 | 22,677 | 21,944 | 11,447 | 20,647 |
| Common Stock Repurchased | -125,023 | -125,023 | -125,023 | N/A | -311,429 |
| Other Financing Activity | -75,220 | -73,224 | -69,412 | -67,163 | -63,469 |
| Financing Cash Flow | $-873,380 | $-948,820 | $-937,991 | $-813,466 | $20,516 |
| Exchange Rate Effect | 6,555 | 6,522 | 6,319 | 1,695 | -1,675 |
| Beginning Cash Position | 2,412,864 | 2,412,864 | 2,412,864 | 2,412,864 | 1,506,310 |
| End Cash Position | 1,391,899 | 1,326,070 | 1,189,880 | 1,861,946 | 2,412,864 |
| Net Cash Flow | $-1,020,965 | $-1,086,794 | $-1,222,984 | $-550,918 | $906,554 |
| Free Cash Flow | |||||
| Operating Cash Flow | 1,355,773 | 993,255 | 518,639 | 429,784 | 1,395,908 |
| Capital Expenditure | -916,805 | -900,076 | -26,848 | -13,881 | -38,070 |
| Free Cash Flow | 438,968 | 93,179 | 491,791 | 415,903 | 1,357,838 |